3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
18
Phase 2
13
Phase 1/2
4
Phase 4
2
Phase 1
2
Phase NA
1
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Anus Neoplasms
2
Virus Diseases
1
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Adenoviridae Infections
1
Interventions
Gemcitabine
6
Carboplatin
3
valrubicin
2
Cisplatin
2
vinflunine
1
toripalimab
1
pertuzumab
1
disitamab vedotin
1
cabazitaxel
1
apaziquone
1
XRP6258
1
Watchful Waiting
1
Vinblastine
1
Trastuzumab
1
Transurethral Resection of Bladder
1
Tranexamic Acid
1
Saline Solution
1
RC48 antibody
1
Oncolytic Virotherapy
1
Mitomycin
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Interferons
1
Interferon-alpha
1
Gabapentin
1
Circulating Tumor DNA
1
Celecoxib
1
BCG Vaccine
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Urinary Bladder Neoplasms
×
Mitomycin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled